Business combination (Details) $ in Thousands			12 Months Ended
	Oct. 15, 2025 shares	Apr. 11, 2024 USD ($) Program shares	Dec. 31, 2024 USD ($)	Dec. 31, 2025 USD ($)
Business Acquisition [Line Items]
Contingent consideration			$ 8,738	$ 3,757
Impairment of goodwill			4,327
Clade Therapeutics, Inc
Business Acquisition [Line Items]
Additional preclinical-stage programs | Program		3
Shares of the stock consideration | shares		3,741,646
Contingent consideration		$ 10,000
Shares of the stock consideration issued | shares	784,128	784,128
Acquisition related costs			$ 895	$ 0
Clade Therapeutics, Inc | Discount for marketability
Business Acquisition [Line Items]
Contingent consideration		$ 2,600
Clade Therapeutics, Inc | Discount rate
Business Acquisition [Line Items]
Contingent consideration		$ 8,883
Contingent consideration (in percentage)			26.9